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RESEARCH ARTICLE Open Access
Incorporating assessment of the cervical
facet joints in the modified Stoke
ankylosing spondylitis spine score is of
additional value in the evaluation of spinal
radiographic outcome in ankylosing
spondylitis
Fiona Maas1*, Suzanne Arends1,2, Elisabeth Brouwer1, Hendrika Bootsma1, Reinhard Bos2, Freke R. Wink2
and Anneke Spoorenberg1,2
Abstract
Background: To aim was to investigate the additional value of incorporating the de Vlam cervical facet joint score
in the modified ankylosing spondylitis (AS) spine score (mSASSS) for the evaluation of spinal radiographic outcome
in AS.
Method: Baseline and 4-year radiographs from 98 consecutive patients from the Groningen Leeuwarden AS (GLAS)
cohort, who had AS treated with TNF-α inhibitors, were scored by two readers; the vertebral bodies were assessed
according to the mSASSS (0–72) and cervical facet joints (C2–C7) were assessed according to the method of de
Vlam (0–15). The combined AS spine score (CASSS) was calculated as the sum of both total scores (range 0–87) and
compared with the original mSASSS according to three aspects of the Outcome Measures in Rheumatology Clinical
Trials (OMERACT) filter: feasibility, discrimination, and truth.
Results: Feasibility: the CASSS was calculated in 91% of the patients. No additional radiographs were necessary and
the assessment took only a few extra minutes. Discrimination: both scoring methods had excellent inter-observer
reliability (intra-class correlation coefficient (ICC) status scores >0.99, progression scores 0.92). Incorporating the
cervical facet joints did not result in an increase in measurement error. The CASSS detected more patients with
definite damage (61% vs. 57%) and definite progression (55% vs. 48%). Truth: higher CASSS scores at baseline and
higher progression scores were seen in 41 (46%) and 22 (25%) patients, respectively. Cervical rotation correlated
better with cervical CASSS than with cervical mSASSS (Spearman’s rho = 0.68 vs. 0.59).
Conclusions: The CASSS is a relevant and easy modification of the mSASSS. It captures more patients with AS who
have spinal radiographic damage and progression, which is of great additional value in the evaluation of
radiographic outcome in this heterogeneous and overall slowly progressing disease.
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Background
Evaluation of structural damage is essential for the diag-
nosis and monitoring of ankylosing spondylitis (AS).
The primary locations of interest are the sacroiliac joints
and the spine. Changes in the sacroiliac joints are espe-
cially important for diagnosis, whereas changes in the
spine are more sensitive for monitoring disease outcome
[1]. Many sites in the spine can be evaluated including
the vertebral bodies, vertebral margins and ligaments,
intervertebral spaces, and the facet joints [1].
Until now, the modified Stoke AS spine score
(mSASSS) is found to be the best and most widely used
scoring method to assess evidence of spinal damage on
conventional radiographs in randomized controlled trials
(RCTs) and cohort studies [2]. This scoring method in-
cludes the anterior elements of the cervical and lumbar
spine. Despite good reliability of the scoring method, the
mSASSS has only moderate sensitivity to change [3]. In
our previous analysis in 210 patients with AS treated
with TNF-α, the smallest detectable change (SDC) for 2-
year progression rates was larger than the mean progres-
sion at the group level (2.3 vs. 1.6, respectively) [4]. SDC
refers to the change in scores that can be detected with-
out measurement error [5]. This indicates that the mean
observed progression at the group level might be a result
of measurement error instead of representing “real” pro-
gression. For progression over a time period ≥4 years,
the SDC was smaller than the mean progression suggest-
ing that at least 4 years of follow up is needed for suffi-
cient discriminatory power of the mSASSS to detect
changes.
The change in radiographic evidence of damage is an
important subject of interest in monitoring the effects of
treatment on spinal radiographic progression in clinical
studies. However, this is hampered by the nature of AS,
a slowly and very heterogeneously progressing disease
[6, 7]. Therefore, researchers have attempted previously
to improve the performance of the mSASSS by incorpor-
ating more spinal elements into the scoring method. In-
cluding anterior elements of the lower part of thoracic
spine (T10–T12) in the mSASSS has resulted in higher
status and progression scores and a larger proportion of
patients identified with (new) syndesmophytes compared
to the original mSASSS [8]. However, in a longitudinal
study including 809 radiographs from 195 patients with
AS, in most cases the three additional thoracic vertebrae
were not visible on lateral radiographs of the lumbar
spine (in 64% of the radiographs), which is an important
limitation to feasibility [9].
Besides the anterior elements of the vertebral bodies
as scored in the mSASSS, the facet joints or zygapophy-
seal joints are frequently affected in AS [10–12] The
presence of facet joint damage is associated with longer
disease duration, greater disease activity, and most
importantly, with worse spinal mobility [10, 12]. Longi-
tudinal studies on the course of spinal mobility showed
that the majority of patients with AS develop moderate
to severe impairment of spinal mobility. Patients with
severe spinal restrictions had severe spinal deformity
[13, 14]. Due to the anatomy of the facet joints, damage
to these joints results in reduced cervical rotation [12].
Reduced cervical rotation hampers patients in all kinds
of daily activities. Therefore, inclusion of the facet joints
in a radiographic scoring method seems clinically
relevant.
The presence and development of radiographic evi-
dence of damage in the facet joints is not always concur-
rent with damage or radiographic progression of the
anterior elements of the spine [10, 12]. In our recent
study in 99 patients with AS treated with TNF-α inhibi-
tors, we found that the majority of patients who devel-
oped new ankylosis of the cervical facet joints did not
develop new syndesmophytes in the cervical spine [12].
These findings indicate that evaluation of the cervical
facet joints in addition to the anterior elements of the
spine could improve construct validity and possibly also
the sensitivity of the mSASSS to change.
Radiographic damage of facet joints can be scored with
the method of de Vlam et al. [10] In particular, the cer-
vical facet joints are easy to score on lateral radiographs
[10, 15], which is in contrast with scoring the lumbar
facet joints. For this, three-quarter-oblique lumbar spine
radiographs are needed. However, the reproducibility of
oblique radiographic assessment might be limited [16].
Most important, the cervical facet joints can be scored
more reliably than the lumbar facet joints [10].
The aim of the present study was to investigate the add-
itional value of incorporating the de Vlam cervical facet
joint score in the mSASSS for the evaluation of spinal
radiographic outcome in AS. In order to investigate the
applicability of a new scoring method, the Outcome Mea-
sures in Rheumatology Clinical Trials (OMERACT) filter
has been proposed, which includes three aspects: feasibil-
ity, discrimination, and truth [17, 18]. The combined AS
spine score (CASSS), a composite scoring method, was
compared with the original mSASSS according to these
three aspects of the OMERACT filter.
Methods
The present analysis was performed in 98 consecutive
patients from the Groningen Leeuwarden AS (GLAS)
cohort study, who had AS and for whom lateral-
projection radiographs of the cervical and lumbar spine
were available at baseline and after 4 years of follow up.
All patients were treated with TNF-α inhibitors because
of persistent high disease activity despite conventional
treatment. As described previously, the GLAS cohort is
a large ongoing, prospective, longitudinal, observational,
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Dutch cohort study in which patients are followed ac-
cording to a fixed protocol and treated according to the
national and international guidelines [4, 12]. Patients
were 18 years or older, and fulfilled the modified New
York criteria for AS and the assessment of spondyloar-
thritis (ASAS) criteria for starting TNF-α blocking
therapy [19].
The GLAS cohort was approved by the local ethics
committees of the Medical Center Leeuwarden (MCL)
and the University Medical Center Groningen (UMCG),
and all patients gave written informed consent according
to the Declaration of Helsinki.
Radiological assessments
Lateral radiographs of the cervical and lumbar spine
were scored independently by two trained readers (FM
and RC). The anterior corners of the vertebrae (lower
C2 to upper T1) were scored according to the mSASSS
(range 0–72): 0 = normal, 1 = erosion, sclerosis, and/or
squaring, 2 = non-bridging syndesmophyte, and 3 =
bridging syndesmophyte [2, 3]. In addition, the cervical
facet joints (C2–C3 to C6–C7) were scored according to
the method of de Vlam et al.: 0 = normal, 1 = joint space
narrowing or erosion, 2 = partial blurring or ankylosis, and
3 = complete blurring or ankylosis (range 0–15) [10, 12].
Abnormalities related to degenerative changes, defined as
a reduction in intervertebral disk space height and hori-
zontal bone spurs (>45°) at the facet joints and/or verte-
bral bodies [20], were not taken into account and
therefore not scored. All patient identifying information
and the performance dates were removed from the radio-
graphs in order to blind readers to patient characteristics
and time sequence. Scoring radiographic progression with
unknown time sequence was used to diminish reader bias,
as all patients were treated with TNF-α inhibitors.
For both scoring methods, a total score was calculated
based on the average of the total scores of both readers.
A third reader (AS) independently reassessed the radio-
graphs in case of discrepancy in the total scores above
the 95% limits of agreement or when there was discrep-
ancy in the presence of non-bridging or bridging syndes-
mophytes and the presence of partial or complete
ankylosis of the facet joints. The score of the primary
reader closest to the third reader was used.
A composite score of the mSASSS and the total facet
joint score was calculated by summing the total scores
of both scoring methods. This combination score was
named the combined AS spine score (CASSS) and had a
scoring range of 0–87. For the mSASSS, the presence or
development of definite damage was defined as the pres-
ence or development of ≥1 non-bridging or bridging
syndesmophyte. In the CASSS, the presence or develop-
ment of definite damage was defined as the presence or
development of (partial) ankylosis in ≥1 facet joints or
the presence or development of ≥1 non-bridging or
bridging syndesmophytes [12].
OMERACT filter
The OMERACT filter consists of three aspects in order
to judge the applicability of measurement instruments:
feasibility, discrimination, and truth [17, 18]. The CASSS
was compared with the original mSASSS as the gold
standard according to these three aspects of the OMER-
ACT filter.
Feasibility
The feasibility aspect of the OMERACT filter focuses on
the question: “Can the measure be applied easily, given
constraints of time, money, and interpretability?” To an-
swer this question, information was given about required
radiographs, the time needed for scoring, and the ability
to score and obtain total scores for both the mSASSS
and CASSS.
Discrimination
The discrimination aspect of the OMERACT filter ad-
dresses the question: “Does the measure discriminate be-
tween situations of interest?” These situations can relate
to states at one time point or change in states over time.
The discrimination aspect captures reliability and sensi-
tivity to change. Inter-observer reliability for the
mSASSS and the CASSSS status and progression scores
was analyzed using the ICC (two-way mixed effects
model, single measures, absolute agreement). Bland and
Altman plots were constructed and the SDCwas calcu-
lated as:
1:96  SDΔðProgression scoreÞ=ð√2√kÞ
in which k represents the number of readings) [4], to ex-
plore systemic error and measurement error. Cohen’s
kappa and the percentage of absolute agreement were
used to explore the inter-observer reliability of measur-
ing the presence or development of definite damage ac-
cording to both scoring methods. ICCs and kappas of
0.00–0.20 were interpreted as poor, of 0.20–0.40 as fair,
of 0.40–0.60 as moderate, of 0.60–0.80 as good, and of
0.80–1.00 as excellent [21].
For sensitivity to change, the mean and median
mSASSS and CASSSS status and progression scores
were reported and the standardized response mean
(SRM: the average of the progression scores divided by
SD of the progression scores) was calculated. An SRM
<0.5 was interpreted as small, 0.5–0.8 as moderate, and
>0.8 as large [22]. In addition, the percentage of patients
with maximal scores at baseline (ceiling effect) (and
thus, not able to be identified with progression accord-
ing to the scoring methods), and the percentage of
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patients with progression >0, with progression ≥ the
SDC, and with definite progression during 4 years of
follow-up were reported.
Truth
The truth aspect of the OMERACT filter focuses on the
questions: “Is the measure truthful, does it measure what
is intended? Is the result unbiased and relevant?” Infor-
mation about the relevance of scoring the cervical facet
joints was investigated by examining the absolute differ-
ences in status and progression scores of the CASSS
compared to the mSASSS using the Wilcoxon signed-
rank test. The CASSS and mSASSS had a common
element of construct validity because they both included
the anterior elements of the spine. The construct validity
of incorporating assessment of the cervical facet joints
in the mSASSS was evaluated by comparing the damage
and progression of damage in the cervical facet joints to
the vertebral bodies scored in the mSASSS.
Correlation between the mSASSS and the total facet
joint score was investigated using Spearman’s correlation
coefficient. In addition, the correlation between the
mSASSS or the CASSS and spinal mobility measures
(cervical rotation, occiput-to-wall distance, lateral spinal
flexion, modified Schober test, and chest expansion),
physical function (Bath AS functional index (BASFI)),
and quality of life (AS quality of life (ASQoL) question-
naire) was investigated using Spearman’s correlation co-
efficients. Correlation of 0.00–0.20 was interpreted as
very weak, 0.20–0.40 as weak, 0.40–0.60 as moderate,
0.60–0.80 as strong and 0.80–1.00 as very strong [21].
Data on cervical rotation were only available at 4 years
in the GLAS cohort. [12] Therefore, correlation between
scores and this measurement was investigated at 4 years
instead of at baseline.
Additional statistical analysis
Descriptive statistics were used; results were expressed
as number of patients (%), mean ± SD or median (IQR)
for categorical, normally distributed and non-normally
distributed data, respectively. The chi-square or Fisher’s
exact test, independent samples t test, and Mann-
Whitney U test were used as appropriate to compare
groups. A p value ≤0.05 was considered statistically sig-
nificant. Statistical analysis was performed using IBM
SPSS Statistics 22 (SPSS, Chicago, IL, USA).
Results
Study population
The baseline characteristics of the 98 patients with AS
for whom spinal radiographs were available are de-
scribed in Table 1. Patients had high disease activity at
baseline, which reduced rapidly after start of TNF-α
blocking therapy and stabilized during follow up (mean
Bath ankylosing spondylitis disease activity index (BAS-
DAI) was 3.0 ± 2.1, mean ankylosing spondylitis disease
activity score (ASDAS) 2.0 ± 0.9, and median C-reactive
protein (CRP) 3 (IQR 2–7) at 4 years). Baseline charac-
teristics such as male gender, age, symptom duration,
and human leukocyte antigen (HLA)-B27 status were
comparable to other AS cohorts.
Feasibility
CASSS was assessed on the same cervical radiographs as
used for the mSASSS and the assessment took only a
few extra minutes. Total scores for the mSASSS were
calculable in 94 (96%) patients and total scores for
CASSS were calculable in 89 (91%) patients; >3 vertebral
edges and ≥1 facet joint were not visible in 2 patients,
>3 vertebral edges were not visible in 2 patients, and ≥1
Table 1 Baseline characteristics of the AS study population
All patients Patients with
available CASSS
n = 98 n = 89
Male gender 74 (76) 66 (74)
Age (years) 41.8 ± 11.2 41.0 ± 11.1
Symptom duration (years) 16 (7–24) 16 (7–24)
Time since diagnosis (years) 7 (2–15) 7 (2–16)
HLA-B27+ 82 (84) 74 (83)
BMI (kg/m2) 26.1 ± 3.5 25.4 ± 3.0
Current smoker 30 (37) 28 (38)
Total smoking duration (years) 12 (0–25) 12 (0–24)
History of IBD 9 (9) 9 (10)
History of uveitis 27 (28) 25 (28)
History of psoriasis 11 (11) 11 (12)
Peripheral arthritis 21 (21) 18 (20)
NSAID use 79 (85) 72 (85)
DMARD use 23 (23) 23 (26)
BASDAI (0–10) 5.9 ± 1.6 5.8 ± 1.7
ASDASCRP 3.8 ± 0.8 3.8 ± 0.8
CRP (mg/L) 15 (7–25) 15 (7–25)
Occiput-to-wall distance (cm) 5.0 (0.0–11.1) 4.5 (0.0–10.0)
Lateral spinal flexion (cm) 7.9 (5.0–11.5) 8.1 (5.5–11.7)
Modified Schober test (cm) 3.0 (1.2–4.0) 4.5 (0.0–10.0)
Chest expansion (cm) 3.0 (2.0–4.0) 3.0 (2.0–4.0)
BASFI (0–10) 5.6 (3.7–7.1) 5.5 (3.6–7.1)
ASQoL (0–18) 10 (7–13) 9 (7–12)
Values are presented as number of patients (%), mean ± SD, or median (IQR).
Total smoking duration: current and past smoking. Peripheral arthritis:
presence of ≥1 swollen joints (range 0–44). AS ankylosing spondylitis, CASSS
combined AS spine score, HLA human leukocyte antigen, BMI body mass
index, NSAID non-steroidal anti-inflammatory drug, DMARD disease-modifying
antirheumatic drug, BASDAI bath AS disease activity index, ASDAS AS disease
activity score, GDA global disease activity, CRP, C-reactive protein, BASFI bath
AS functional index, ASQoL AS quality of life questionnaire
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facet joint was not visible in 5 patients. Facet joints at
the levels of lower C6 to upper T1 and/or C6–C7 were
not visible in these patients.
For further comparison, we used 89 patients with AS
for whom radiographic data were available for both the
mSASSS and CASSS in all analyses. The baseline charac-
teristics of these patients are shown in Table 1. The nine
patients without CASSS data were significantly older,
had higher body mass index (BMI), worse spinal mobil-
ity, and worse quality of life.
Discrimination
Reliability
Inter-observer reliability was excellent and was similar
for the mSASSS and CASSS with ICCs >0.99 for status
scores and 0.92 for progression scores. Bland and Alt-
man plots revealed no systematic error in either scoring
method (Fig. 1).
For mSASSS, Cohen’s kappa was 0.86 for the presence
of definite damage and 0.87 for the development of
definite damage, with percentages of absolute agreement
of 93% for both definite damage and definite progres-
sion. For CASSS, the reliability and absolute agreement
was even better; Cohen’s kappa was 0.98 for the pres-
ence of definite damage and 0.89 for the development of
definite damage, with percentages of absolute agreement
of 99% and 94%, respectively.
Sensitivity to change
At the group level, mean status scores at baseline were
19.3 ± 18.7 for the mSASSS and 21.8 ± 21.3 for the
CASSS, showing large variation in radiographic damage
according to both methods. Mean progression scores
over 4 years of follow up were 2.7 ± 4.6 and 3.0 ± 4.8, re-
spectively. The SDC using the mSASSS or the CASSS
was smaller than the mean 4-year progression rate
(Table 2). The SRM was 0.59 for the mSASSS and 0.63
for the CASSS (Table 2).
At the individual patient level, the CASSS resulted in
more patients identified with definite damage at baseline
(61% vs. 57%), fewer patients with the maximum score
(1% vs. 3%), and more patients with definite progression
during follow up (55% vs. 48%) (Table 2).
Truth
In comparison to the mSASSS, scoring radiographic
damage using the CASSS resulted in 41 patients (46%)
with higher baseline scores and 22 (25%) with higher
progression scores (Fig. 2). Ten patients (11%) had lower
progression scores as a result of scoring with unknown
time sequence. Differences in scores were seen over the
whole spectrum of the mSASSS, both in patients with-
out damage and in patients with very advanced disease
according to the mSASSS. No fan-out pattern was
observed.
There was moderate correlation between the cervical
facet joint score and the mSASSS (Spearman’s rho =
0.49). There was weak correlation between change in
score for the cervical facet joints over 4 years and
change in the mSASSS (Spearman’s rho = 0.16).
For radiographic damage assessed using either the
mSASSS or the CASSS, there was strong correlation
with the occiput-to-wall distance and with lateral spinal
flexion; there was moderate correlation with the modi-
fied Schober test; and there was weak correlation with
chest expansion and with the BASFI. There was no cor-
relation between damage identified by either the
mSASSS or the CASSS and the ASQoL (Table 3). Cer-
vical rotation at 4 years was somewhat better correlated
with the CASSS than with the mSASSS (Table 3).
Additional analysis using only the cervical mSASSS
(range 0–36) and the cervical CASSS (range 0–51)
showed that the cervical CASSS was more strongly
Fig. 1 Bland and Altman plots show differences between readers in
progression scores in assessed using the modified Stoke ankylosing
spondylitis spine score (mSASSS) (a) and the combined ankylosing
spondylitis spine score (CASSS) (b), plotted against the average scores
of both readers and the 95% limits of agreement (+/− 1.96*SD)
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correlated with cervical rotation (Spearman’s rho = 0.68)
than the cervical mSASSS (Spearman’s rho = 0.59).
Discussion
This is the first study investigating the additional value
of cervical facet joints in the evaluation of spinal radio-
graphic outcome in patients with AS, a slowly progres-
sive disease in which both the anterior and posterior
elements of the spine are affected [1, 7]. The composite
scoring method CASSS, which combines the assessment
of damage at the cervical facet joints (according to de
Vlam) with the assessment of damage at the anterior
corners of the cervical and lumbar vertebral bodies (the
mSASSS), was compared with the original mSASSS
using the three aspects of the OMERACT filter: feasibil-
ity, discrimination, and truth [17, 18].
The feasibility of the CASSS was very good; no extra ra-
diographs were needed, it took only a few extra minutes
to perform the CASSS, and the cervical facet joints were
clearly visible in >90% of the patients. The lumbar facet
joints were not included in the new scoring method be-
cause previous studies have shown that lumbar facet joints
are more difficult to score than cervical facet joints. A
study in 73 patients with psoriatic arthritis (PsA) showed
that lumbar facet joints could be scored on lateral and
anterior-posterior radiographs in 73–82% of the patients
whereas cervical facet joints could be scored in 93–95% of
the patients [15]. In the study of de Vlam et al., the
Table 3 Correlation between radiographic damage assessed
using the mSASSS and CASSS and spinal mobility, physical
function, and quality of life at baseline
mSASSS CASSS
Cervical rotationa −0.56** −0.63**
Occiput-to-wall distance 0.64** 0.67**
Lateral spinal flexion −0.62** −0.61**
Modified Schober test −0.44** −0.45**
Chest expansion −0.33** −0.35**
BASFI 0.24* 0.26*
ASQoL 0.03 −0.01
Correlation is expressed as Spearman’s rho. aAnalysis performed with 4 years
of data. mSASSS modified stoke ankylosing spondylitis spine score, CASSS
combined ankylosing spondylitis spine score, BASFI Bath ankylosing spondylitis
functional index, ASQoL ankylosing spondylitis quality of life questionnaire.
*Statistically significant correlation p ≤ 0.05. **Statistically significant
correlation p ≤ 0.01
Table 2 Status and progression scores and proportion of
patients with damage and progression according to the
mSASSS and the composite CASSS
mSASSS (range 0–72) CASSS (range 0–87)
Status scores
Observed range 0–72 0–87
Mean ± SD 19.3 ± 18.7 21.8 ± 21.3
Median (IQR) 11.3 (5.1–29.9) 13.5 (5.4–36.6)
Definite damage 51 (57) 54 (61)
Maximum score 3 (3) 1 (1)
Progression scores
Observed range −3.5–20.8 −4.3–20.8
Mean ± SD 2.7 ± 4.6 3.0 ± 4.8
Median (IQR) 1.2 (0.0–3.6) 1.6 (0.0–4.2)
SDC 1.8 1.9
SRM 0.59 0.63
Progression >0 64 (72) 64 (72)
Progression ≥ SDC 40 (45) 41 (46)
Definite progression 43 (48) 49 (55)
Values are presented as mean ± SD, median (IQR), or number of patients (%).
mSASSS modified stoke ankylosing spondylitis spine score, CASSS combined
ankylosing spondylitis spine score, SDC smallest detectable change, SRM
standardized response mean
Fig. 2 Differences in status and progression scores when comparing
the composite score (combined ankylosing spondylitis spine score
(CASSS)) (range 0–87) with modified Stoke ankylosing spondylitis
spine score (mSASSS) (range 0–72). X-axis mSASSS status scores at
baseline (a) and progression scores during 4 years of follow-up (b).
Y-axis: differences between mSASSS and CASSS status and
progression scores
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inter-observer and intra-observer reliability was only
poor to moderate for scoring individual lumbar facet
joints on oblique radiographs (weighted kappa for the
stages ranged between 0.19 and 0.52), but there was
moderate to good reliability for scoring individual cer-
vical facet joints on lateral projection radiographs
(weighted kappa ranged between 0.55 and 0.66) [10].
As spinal radiographic progression in AS is a slow and
very heterogeneous process, a reliable scoring method is
needed with low measurement error and good discrimin-
atory properties to detect changes over time. In our study
the inter-observer reliability was excellent for both the
mSASSS and the CASSS, with comparable SDCs (1.8 and
1.9, respectively). This implies that, although it involves
scoring additional sites, the CASSS could be used without
an increase in measurement error. The SDCs were smaller
than the mean mSASSS and CASSS progression rates over
4 years and therefore “real” changes could be assessed
during 4 years of follow up using either scoring method.
The most important benefit of the CASSS over the
mSASSS is that the CASSS had better discriminatory
properties and better construct validity than the mSASSS.
The composite scoring method detected more patients
with definite damage at baseline (61% vs. 57%). Seven per-
cent of the patients with evidence of definite progression
during 4 years of follow up according to the CASSS did
not have progression according to the mSASSS. In
addition, almost half of all patients had higher status
scores and 25% had higher progression scores according
to the CASSS. Differences in scores were found over the
whole spectrum of the mSASSS. This confirms that not
only the vertebral bodies but also the facet joints are fre-
quently involved in AS, even if no damage or progression
is observed or when patients have very advanced disease
according to the original mSASSS [10–12].
There was weak correlation between disease progression
in the facet joints and progression in the vertebral bodies.
This suggests that the damage does not develop in the
facet joints synchronically with the most typical AS-
related damage, i.e., the development of syndesmophytes.
It has been thought that damage in the facet joints is not
specific to AS as these joints are also affected by degenera-
tive changes [23]. The most characteristic degenerative
changes in the facet joints are osteophyte formation (more
horizontally oriented, >45°), joint space narrowing, scler-
osis, and joint irregularity [20]. In patients with degenera-
tive disc disease who are candidates for lumbar spine
surgery, facet joint osteoarthritis was not observed in the
absence of disc degeneration [24]. It is thought that de-
generative changes begin in the disc, followed by changes
in the facet joints [20, 24]. Therefore, the whole structure
at each vertebral level was evaluated in the present study
in order to distinguish between AS-specific changes and
degenerative changes.
In a USA population based study from 1970, cervical
osteoarthritis (not specifically facet joint osteoarthritis)
was very rare before the age of 45 years (prevalence
<2%). The prevalence of cervical osteoarthritis was 19%
in adults aged 45–64 years, and in adults aged 65 years
or older it was 56–57% [25]. The hallmark radiographic-
ally demonstrated characteristic of AS is ankylosis of the
vertebral column. In our study partial or complete facet
joint ankylosis was already evident in 19% of the patients
aged <45 years. In patients aged 45–64 years, 34% had
partial or complete facet joint ankylosis and 33% of pa-
tients aged 65 years or older had ankylosis. Incident par-
tial or complete ankylosis was evident within 4 years of
follow up in 14% of our patients with AS; half of these
patients were younger than 45 years. This shows that
AS-related cervical facet joint involvement begins at a
relatively young age in comparison to osteoarthritis.
In our previous analysis we demonstrated that facet
joint damage is associated with longer symptom dur-
ation, higher disease activity (ASDAS and CRP), worse
spinal mobility (occiput-to-wall distance), and presence
of extra-articular manifestations (inflammatory bowel
disease (IBD), uveitis, and psoriasis) [12]. These findings,
in combination with the strong correlation between
CASSS and cervical rotation, occiput-to-wall distance,
and lateral spinal flexion, as found in the present study,
highlight the fact that damage in the cervical facet joints
is common in AS, and is also evident at a younger age.
Incorporating cervical facet joint scores is therefore of
clinical relevance and improves the construct validity of
the assessment of spinal radiographic damage in AS.
Previously, researchers in the field of PsA also developed
a composite scoring method, the psoriatic arthritis spon-
dylitis radiology index (PASRI). This scoring method com-
bines the mSASSS of at the level of lower T12 to upper S1
and lower C2 to upper C6, the cervical facet joints (pres-
ence or absence of ankylosis), and the sacroiliac joints (SI)
score (modified New York criteria) [13]. Although intra-
observer and inter-observer reliability are excellent for the
PASRI (range 0–72) in AS [26], it is very difficult to reli-
ably score status and progression of disease at the SI joints
in AS [27]. Besides this, the most important advantage of
the CASSS over the PASRI is that the original mSASSS re-
mains intact and, therefore, it is possible to obtain separ-
ate data on the mSASSS and the cervical facet joints. In
this way, the original mSASSS scores in new studies can
easily be compared with scores from former studies using
only the mSASSS.
Our study was the first to investigate radiographic evi-
dence of progression of disease at the cervical facet joints
in patients with AS who had active disease and had started
treatment with TNF-α inhibitors. The results may not be
generalizable to all patients with axial spondyloarthritis
(SpA). As potent biologic agents such as TNF-α inhibitors
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are available for the treatment of active disease in AS, it is
unethical to withhold this treatment long-term in patients
with active disease. Therefore, it was not possible to com-
pare radiographic evidence of progression at the cervical
facet joints in patients with and without TNF-α inhibitors
in order to evaluate the effect of treatment. Further valid-
ation of the CASSS is needed in patients with axial SpA at
different stages of disease duration, disease activity, and
treatment strategies, and in long-term follow up. Data on
radiographic evidence of progression at the vertebral bod-
ies (mSASSS) show that at >4 years of follow up at least
are needed to show radiographic evidence of diminishing
progression during treatment with TNF-α inhibitors in
this disease of overall slow progression [4, 28].
The assessment was performed with unknown time se-
quence to diminish possible reader bias due to know-
ledge of the applied therapy. However, it caused some
negative progression scores (in 11 patients according to
the CASSS and in 19 patients according to the
mSASSS). Excessive bone formation in AS is an irrevers-
ible process, and therefore, negative progression is a re-
sult of measurement error. Reading radiographs in
chronological time order is more sensitive to detect
changes but less appropriate with respect to reader bias
when the applied treatment regimens are known [29].
Future studies should determine the discrimination and
truth aspects of the CASSS scored in chronological time
order when radiographs from patients receiving conven-
tional and biological treatment are randomized.
Conclusions
The CASSS seems a promising scoring method to evalu-
ate spinal radiographic outcome in AS. In our prospect-
ive observational cohort study we demonstrated that
standardized scoring of the cervical facet joints in
addition to the mSASSS is a feasible and reliable modifi-
cation that provides better construct validity than the
original mSASSS. Furthermore, the composite CASSS
captures more patients with radiographic evidence of
spinal disease progression, which is very valuable in this
heterogeneous and overall slowly progressing disease.
Key messages
 Incorporation of the cervical facet joints in the
mSASSS is feasible, reliable and relevant for the
assessment of spinal radiographic outcome in AS
 The combined AS spine score (CASSS) captured more
patients with AS with damage and progression and
correlated better with cervical rotation than mSASSS
 The original mSASSS and the cervical facet joint
score of de Vlam can easily be extracted from the
CASSS
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